CN103356686B - The application of Houttuynoid B in the medicine preparing treatment or preventing chronic heart failure - Google Patents
The application of Houttuynoid B in the medicine preparing treatment or preventing chronic heart failure Download PDFInfo
- Publication number
- CN103356686B CN103356686B CN201310261406.0A CN201310261406A CN103356686B CN 103356686 B CN103356686 B CN 103356686B CN 201310261406 A CN201310261406 A CN 201310261406A CN 103356686 B CN103356686 B CN 103356686B
- Authority
- CN
- China
- Prior art keywords
- heart failure
- chronic heart
- houttuynoid
- treatment
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Do you the invention provides Houttuynoid? does the application of B in the medicine preparing treatment or preventing chronic heart failure, propose Houttuynoid particularly? B is to the therapeutical effect of acute and chronic heart failure.The Houttuynoid that the present invention relates to? the purposes of B in preparation treatment chronic heart failure belongs to first public, because framework types belongs to brand-new framework types, and the activity of its treatment chronic heart failure is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, be used for the treatment of chronic heart failure simultaneously and obviously there is significant progress.
Description
Invention field
The present invention relates to the application of HouttuynoidB in the medicine preparing treatment or preventing chronic heart failure.
Background technology
Heart failure (hearfailure, HF) refers to that cardiac function is abnormal and causes heart pump blood volume can not meet a kind of pathological and physiological condition of tissue metabolism's needs.Cause of disease inducement causes structure function low and Progressive symmetric erythrokeratodermia morbidity because cardiac overload, cardiac muscle itself, the limited any reason of diastole cause initial myocardial damage; And infect, anemia, gestation, childbirth, cardiac arrhythmia, pulmonary infarction, hyperthyroidism, diabetes, suppression heart medicine bring out and increase the weight of HF.Pathogeny thinks that the mechanism that HF occurs to develop is abnormal hemodynamics in the past; The later stage eighties 20th century recognizes that the activation of nerve-endocrine hormone plays an important role (sympathetic ↑ NE ↑ RAS ↑ wait activation); Specify that after the nineties that " Myocardial Remodeling " (remodelling) is the fundamental mechanism causing the generation of heart failure to develop gradually.
The compound H outtuynoidB that the present invention relates to is one and delivers (Chen in 2012, S.D.etal., 2012.HouttuynoidA-E, Anti-HerpesSimplexVirusActiveFlavonoidswithNovelSkeleton sfromHouttuyniacordata.OrganicLetters14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S.D.etal., 2012.HouttuynoidA-E, Anti-HerpesSimplexVirusActiveFlavonoidswithNovelSkeleton sfromHouttuyniacordata.OrganicLetters14 (7), 1772 – 1775.), the purposes of the HouttuynoidB that the present invention relates in preparation treatment chronic heart failure is belonged to first public, because framework types belongs to brand-new framework types, and the activity of its treatment chronic heart failure is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, be used for the treatment of chronic heart failure simultaneously and obviously there is significant progress.
Summary of the invention
The invention provides the application of HouttuynoidB in the medicine preparing treatment or preventing chronic heart failure.
Described compound H outtuynoidB structure is as shown in formula I:
The purposes of the HouttuynoidB that the present invention relates in preparation treatment chronic heart failure belongs to first public, because framework types belongs to brand-new framework types, and the activity of its treatment chronic heart failure is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, be used for the treatment of chronic heart failure simultaneously and obviously there is significant progress.
Detailed description of the invention
The preparation method of compound H outtuynoidB involved in the present invention is see document (Chen, S.D.etal., 2012.HouttuynoidA-E, Anti-HerpesSimplexVirusActiveFlavonoidswithNovelSkeleton sfromHouttuyniacordata.OrganicLetters14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoidB tablet involved in the present invention:
Get 20 g of compound HouttuynoidB, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound H outtuynoidB capsule involved in the present invention:
Get 20 g of compound HouttuynoidB, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example HouttuynoidB is on the impact of chronic heart failure rat
Test method and result
Rat 100, male and female half and half, get 100 lumbar injection doxorubicin hydrochloride 2mg/kg, 1 time weekly, totally 6 weeks.Be divided into 10 groups at random, i.e. NS group, Captopril tablets 12.5mg/kg group, gastric infusion HouttuynoidB0.2mg/kg group, gastric infusion HouttuynoidB2.5mg/kg group, gastric infusion HouttuynoidB5.0mg/kg group.Within 5th week, rise and give each group of HouttuynoidB gavage, administration 21 days every day.20% urethane 1.1g/kg intraperitoneal injection of anesthesia, peeling operation trachea intubate, the total tremulous pulse in right side of simultaneously dissociating, inserts homemade heart catherization (diameter 1mm is full of 1% heparin) through it, traces blood pressure curve; Continue again to insert, make it enter left ventricle by left arterial lobe, trace intraventricular pressure curve, Automatic analysis left ventricular systolic pressure (LVSP), maximum the climbing speed (+dp/dt of intraventricular pressure
max), intraventricular pressure maximum falling speed (-dp/dt
max) and survey the data such as myocardium maximal velocity of contraction (Vpm).Separately get 10 rats as Normal group, do not give doxorubicin hydrochloride, all the other operations are with above-mentioned, and between group, T inspection, carries out statistical procedures.
Table 1HouttuynoidB is on the impact (n=10) of chronic heart failure Cardiac Function in Rat
Compare with NS group,
△: p<0.05,
△ △: p<0.01
Table 1 result of the test shows that HouttuynoidB gastric infusion 0.2mg/kg group can raise the LVSP of the Heart Failure Wistar Rats caused by doxorubicin hydrochloride ,+dp/dt
max,-dp/dt
maxwith the reduction (comparing with NS group, P<0.05) of Vpm; HouttuynoidB gastric infusion 2.5mg/kg, 5.0mg/kg significantly can raise the LVSP of the Heart Failure Wistar Rats caused by doxorubicin hydrochloride ,+dp/dt
max,-dp/dt
maxwith the reduction (comparing with NS group, P<0.01) of Vpm.
Conclusion: HouttuynoidB has the effect of significant treatment or preventing chronic heart failure, can be used for preparing the medicine for the treatment of or preventing chronic heart failure.
Claims (1)
1.HouttuynoidB preparation treatment or preventing chronic heart failure medicine in application, described compound H outtuynoidB structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310261406.0A CN103356686B (en) | 2013-06-24 | 2013-06-24 | The application of Houttuynoid B in the medicine preparing treatment or preventing chronic heart failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310261406.0A CN103356686B (en) | 2013-06-24 | 2013-06-24 | The application of Houttuynoid B in the medicine preparing treatment or preventing chronic heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103356686A CN103356686A (en) | 2013-10-23 |
| CN103356686B true CN103356686B (en) | 2016-01-20 |
Family
ID=49359502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310261406.0A Active CN103356686B (en) | 2013-06-24 | 2013-06-24 | The application of Houttuynoid B in the medicine preparing treatment or preventing chronic heart failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356686B (en) |
-
2013
- 2013-06-24 CN CN201310261406.0A patent/CN103356686B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.;Chen, S. D.等;《Organic Letters》;20121231;第14卷(第7期);1772-1775 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356686A (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105412101A (en) | Application of Virosaines A in preparing medicine for treating or preventing chronic heart failure | |
| CN103585148B (en) | Application of Nitrosporeusines A in chronic heart failure treatment or prevention medicines | |
| CN103356686B (en) | The application of Houttuynoid B in the medicine preparing treatment or preventing chronic heart failure | |
| CN103356671B (en) | The application of Houttuynoid C in the medicine preparing treatment or preventing chronic heart failure | |
| CN103356673B (en) | The application of Houttuynoid A in the medicine preparing treatment or preventing chronic heart failure | |
| CN103372000B (en) | The application of Chukrasone B in the medicine preparing treatment or preventing chronic heart failure | |
| CN103393698B (en) | The application of Chukrasone A in the medicine preparing treatment or preventing chronic heart failure | |
| CN103550225B (en) | The application of Phyllanthoid A in preparation treatment or preventing chronic heart failure medications | |
| CN103768050B (en) | Eryngiolide A treatment or preventing chronic heart failure medicine in application | |
| CN103599106B (en) | The application of Caesanines D in preparation treatment or preventing chronic heart failure medications | |
| CN103610672B (en) | The application of Hippolachnin A in treatment or preventing chronic heart failure medications | |
| CN105287452A (en) | Use of Periconianone A in preparation of drug for treating or preventing chronic heart failure | |
| CN105412064A (en) | Application of Salvadione C in preparation of drug for treating or preventing chronic heart failure | |
| CN105395543A (en) | Applications of Verrulactone C in preparation of medicines treating or preventing chronic heart failure | |
| CN104997766A (en) | Medicine for treating or preventing chronic heart failure and application of medicine | |
| CN103356570A (en) | Application of Sarcaboside B in medicine used for treating or preventing chronic heart failure | |
| CN103356548A (en) | Application of Sarcaboside A in preparation of drug for treating or preventing chronic heart failure | |
| CN103381180A (en) | Application of Houttuynoid E in drug for treating or preventing chronic heart failure | |
| CN103356670A (en) | Application of Houttuynoid D in medicine for treating or preventing chronic heart failure | |
| CN103463006A (en) | Application of racemosins A in preparation of medicine treating or preventing chronic heart failure | |
| CN103479621A (en) | Application of Neonectrolide A to in preparation of medicament for treating or preventing chronic heart failure | |
| CN103316028A (en) | Application of Polyflavanostilbene A in preparation of drug for treating or preventing chronic heart failure | |
| CN102988347A (en) | Application of Aphanamixoid A for preparing medicine for treating or preventing chronic heart failure | |
| CN103372007B (en) | Chukrasone B treats in preparation or prevents the application in the medicine of acute heart failure | |
| CN103263421A (en) | Application of myriberine A in preparation of medicaments for treating or preventing chronic heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151022 Address after: 266000 Licang, Qingdao, No. nine East water road, No. 320, No. Applicant after: Gu Xiangmao Address before: 210009 Gulou District, Jiangsu, Nanjing Gu Ping Kong, No. 4 Applicant before: Ding Shengyu |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhu Ping Inventor after: Zhuang Jian Inventor after: Zheng Shaoyi Inventor after: Ding Hao Inventor after: Li Jiaxin Inventor after: Zhao Mingyi Inventor after: Zhu Shuoji Inventor after: Shu Gang Inventor after: Tian Weimao Inventor before: Ding Shengyu |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151118 Address after: Room 27, No. 103, compound 91, Dongchuan Road, Yuexiu District, Guangdong, Guangzhou Applicant after: Zhu Ping Address before: 266000 Licang, Qingdao, No. nine East water road, No. 320, No. Applicant before: Gu Xiangmao |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151124 Address after: 510080 No. 96, Dongchuan Road, Guangzhou, Guangdong, Yuexiu District Applicant after: Guangdong Prov. Cardiovascular disease Inst. Applicant after: Guangdong General Hospital Address before: 510000, room 27, No. 103, compound 91, Dongchuan Road, Yuexiu District, Guangdong, Guangzhou Applicant before: Zhu Ping |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |